Thanks for this, I do consider severity to include hospitalization and death: https://www.reuters.com/business/healthcare-pharmaceuticals/pfizerbiontech-covid-1

Thanks for this, I do consider severity to include hospitalization and death: https://www.reuters.com/business/healthcare-pharmaceuticals/pfizerbiontech-covid-19-vaccine-effectiveness-drops-after-6-months-study-2021-10-04/ https://www.reuters.com/business/healthcare-pharmaceuticals/... Note that it's now talking about effectiveness in transmissibility, rather than what defined effectiveness when they were being tested which was hospitalization and death -- which is still at 90% after 6 months, including against Delta. I do follow many nurse friends of mine who share daily counts of local ICU case increases, and very much agree that I consider ICU capacity (or hospital in general) to be something that must be monitored. That was a statistic I didn't have -- and thank you spurred some more study digging and I found this: https://www.nejm.org/doi/full/10.1056/NEJMoa2115624 https://www.nejm.org/doi/full/10.1056/NEJMoa2115624 This feels pretty relevant, 90% reduction in mortality between those who got a booster and those who did not (for ages 50+), though I'm still looking at people for my age. Anyway-- thanks, this is useful, going to dig more